Wall Street analyst estimates for Viridian Therapeutics, Inc. (VRDN): consensus price target, buy/hold/sell recommendations and forecasts for revenue and EPS for the upcoming fiscal years.
Viridian Therapeutics, Inc. is a biotechnology firm committed to creating therapies for patients afflicted by serious illnesses. Its primary development efforts include VRDN-001, a humanized monoclonal anti-IGF-1R antibody currently advancing through Phase 1/2 clinical trials for thyroid eye disease (TED).
Consensus price target
$36.43 (+48 % vs price $24.67)
between $26.00 and $43.00 · 3 targets published in the last quarter
Closing price, Oct 30
A twelve-month target is not a fair value: compare it with the range in the Valuation tab.
Revenue and EPS estimates
| Fiscal year | Revenue (average) | Revenue (low – high) | EPS (average) | Analysts |
|---|---|---|---|---|
| 2027E | $238M | $183M – $384M | $-2.55 | 11 |
| 2028E | $608M | $330M – $1.4B | $-0.25 | 10 |
Figures in USD · consensus as of October 29, 2026
Analyst Consensus
| Strong Buy | 0 |
| Buy | 14 |
| Hold | 2 |
| Sell | 0 |
| Strong Sell | 0 |
| Total analysts | 16 |
| Avg rating (−2 sell to +2 buy) | 0.88 |
Recent Earnings Surprises
| Date | EPS Actual | EPS Est. | vs Est. |
|---|---|---|---|
| 2026-11-04 | $-1.02 | ||
| 2026-08-06 | $-1.05 | $-1.03 | -1.9% |
| 2026-05-05 | $-0.90 | $-1.06 | +15.1% |
| 2026-02-26 | $-1.08 | $-0.90 | -20.0% |
| 2025-11-05 | $-0.34 | $-0.82 | +58.5% |
| 2025-08-06 | $-1.00 | $-1.00 | +0.0% |
| 2025-05-06 | $-0.87 | $-0.95 | +8.4% |
| 2025-02-27 | $-0.81 | $-1.05 | +22.9% |
Valuation Ratios
| Price / Book | 4.02 |
| EV / EBITDA | -7.82 |
| Dividend Yield | 0.00% |
Income Statement (10y)
| Year | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $3.3M | $4.0M | $8.4M | $4.5M | $1.1M | $3.0M | $1.8M | $314,000 | $302,000 | $70.8M |
| Cost of Revenue | $2.5M | $19.6M | $30.4M | 0 | $28.3M | 0 | 0 | 0 | 0 | 0 |
| Gross Profit | $789,000 | -$15.6M | -$22.0M | $4.5M | -$27.3M | $3.0M | $1.8M | $314,000 | $302,000 | $70.8M |
| Research & Development | $888,000 | $19.6M | $30.4M | $34.8M | $28.3M | $56.9M | $100.9M | $159.8M | $238.3M | $338.9M |
| Selling, General & Admin | $9.6M | $10.9M | $11.0M | $11.6M | $13.3M | $25.8M | $35.2M | $95.0M | $61.1M | $95.3M |
| Operating Expenses | $10.5M | $30.5M | $41.5M | $46.4M | $83.1M | $82.7M | $136.1M | $254.8M | $299.3M | $434.2M |
| Operating Income | -$12.5M | -$26.5M | -$33.1M | -$42.0M | -$110.4M | -$79.7M | -$134.3M | -$254.4M | -$299.0M | -$363.4M |
| EBITDA | -$12.2M | -$25.8M | -$31.5M | -$40.8M | -$40.3M | -$79.3M | -$129.1M | -$235.4M | -$266.4M | -$337.2M |
| Interest Expense | $95,000 | $383,000 | $873,000 | $835,000 | $508,000 | $3,000 | $486,000 | $1.8M | $3.0M | $4.9M |
| Pre-tax Income | -$12.7M | -$26.5M | -$32.7M | -$41.9M | -$110.7M | -$79.4M | -$129.9M | -$237.7M | -$269.9M | -$342.6M |
| Income Tax | $95,000 | $95,000 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Net Income | -$12.7M | -$26.5M | -$32.7M | -$41.9M | -$110.7M | -$79.4M | -$129.9M | -$237.7M | -$269.9M | -$342.6M |
| EPS | $-17.57 | $-20.66 | $-16.57 | $-20.31 | $-31.20 | $-6.66 | $-3.91 | $-5.31 | $-3.98 | $-3.32 |
| EPS (Diluted) | $-17.57 | $-20.66 | $-16.57 | $-20.31 | $-31.20 | $-6.66 | $-3.91 | $-5.31 | $-3.98 | $-3.32 |
| Shares Outstanding (Diluted) | 721,410 | 1.3 M | 2.0 M | 2.1 M | 3.6 M | 11.9 M | 32.1 M | 44.8 M | 67.9 M | 84.8 M |
Price
| Price | $24.67 (closing price, October 30, 2026) |
| Market Cap | $2.8B |
| Exchange | NASDAQ |
| Country | US |
Related companies: VRTX · 0QZU.L · REGN · MRNA · 0R2M.L · ARGX · 0QNO.L · RVMD
Explore sector: Healthcare · Biotechnology
More sections of VRDN: Overview · Financials · Valuation · Statistics · Technical · Ownership · News · Events
Discover more: Weekly Radar: the S&P 500 through the Buffett and Lynch methods · Companies that pass the Buffett method today · Companies that pass the Lynch method today · Stocks that pass Graham's defensive investor test today · Investment Academy — learn to analyze stocks